Repurposing AKT Inhibitors for the Treatment of Protein Misfolding and Protein Trafficking Diseases

Case ID:

Wayne State University researchers have demonstrated that inhibition of pro-survival kinase, AKT, using the transgene, Trb3, expressed in oligodendrocytes, leads to less brain white matter than controls. Moreover, Trb3 introduction into an animal model of the human disease, Pelizaeus Merzbacher disease (PMD) leads to less myelin thickness and fewer disease symptoms than untreated animals. These results suggest inhibiting AKT may ameliorate the symptoms of PDM and other diseases with similar or analogous pathophysiology such as Alzheimer and Parkinson’s disease to name a few.

Commercial Applications

·         We are seeking industrial partners to further develop this technology by characterizing biologic or small molecule inhibitors of AKT.

·         Potential to develop chemical or protein-based inhibitors or ATK to treat neurodegenerative diseases such as; Alzheimer’s, Parkinson’s, and Huntington disease; Charcot-Marie-Tooth disease, amyotrophic lateral sclerosis, multiple sclerosis and prion diseases.

Patent Status

Patent pending

Tech ID


Patent Information:
For Information, Contact:
Joan Dunbar
Associate Vice President for Technology Commercialization
Wayne State University
(313) 577-5542
Alexander Gow
Cherie Southwood
Alzheimer's Disease